TargetBeta
CCR5
C-C motif chemokine receptor 5 · also CKR-5, CC-CKR-5, CKR5, CD195 · CD molecules
2 programs in company-led studies act on CCR5, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Maravirocrule | GlaxoSmithKline | phase 4 | 261 running | – | NCIt |
| leronlimabrule | CytoDyn | phase 3 | 201 running | – | NCIt |
Conditions their studies are in
- Acquired Immunodeficiency Syndrome, 2 programs
- HIV Infections, 2 programs
- Arthritis, Rheumatoid, 1 program
- Colorectal Neoplasms, 1 program
- COVID-19, 1 program
- Infections, 1 program
- Post-Acute COVID-19 Syndrome, 1 program
- Triple Negative Breast Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 1, 2026Maraviroc · GlaxoSmithKline · phase 4 · NCT06974084
- Jan 2028leronlimab · CytoDyn · phase 3 · NCT06699836
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.